A Phase IV, Placebo-controlled Single Sequence Crossover Study to Evaluate the Effect of Repeat Oral Doses of Lapatinib on Cardiac Repolarization in Patients With Advanced Cancer.
Phase of Trial: Phase IV
Latest Information Update: 22 Jun 2016
At a glance
- Drugs Lapatinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 12 May 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 12 Apr 2013 Planned end date changed from 1 Dec 2012 to 1 Jul 2014 as reported by ClinicalTrials.gov.
- 08 Dec 2011 Actual initiation date (Nov 2011) added as reported by ClinicalTrials.gov.